Two groups in a Lebanese weight-loss study reached almost the same average body mass index (BMI) after two years. One had taken Ozempic and the other had undergone bariatric surgery. The similar endpoints hide a wide gap at the start. The surgery group began more than seven BMI points higher. The people counted on the Ozempic side had also stayed on the medicine for two years, a detail that matters to anyone weighing what might happen after starting it. Khairallah and colleagues in JPRAS Open
Similar final BMI, different starting points
The pilot study, published online November 6, 2026, looked back at 100 adults treated from 2019 to 2023 in Jbeil, Lebanon. Researchers identified 50 people treated with Ozempic through clinics and 50 who had bariatric surgery through hospitals. The researchers described the adults as eligible for both options at baseline. The study included people with type 2 diabetes. The groups reflected treatments people had already received. The published regimen for the medicine group was 1 mg of semaglutide weekly. Study design and intervention
In the Ozempic group, average BMI went from 34.23 to 29.55. In the surgery group it went from 41.65 to 29.34. That works out to drops of 4.68 and 12.31 BMI points when you subtract the published group averages. These are descriptive changes in two groups that started in different places. A final BMI tells you where a group ended up, while a change from baseline tells you how far it moved. The group with the larger drop began with a substantially higher BMI, so the gap in those drops leaves the effect of treatment itself uncertain. JPRAS Open, Table 1
Who counted in the Ozempic group?
The researchers excluded people who discontinued Ozempic before two years or did not take it as prescribed. They also excluded people who used it after surgery. That leaves a comparison about people who continued the medicine, and a separate question about all the people who might start it. For example, the study leaves open how many starters would stop because of side effects, affordability or other reasons, and what would happen to their weight afterward. Participants reported weights by phone or online questionnaire, so recall could also affect the measurements. Eligibility and study limitations
The paper found no statistically significant difference in average BMI between the groups at six, 12 or 24 months. A small study can miss a difference, and proving equivalence would require a design set up to test whether a difference falls within a clinically acceptable range. Here, treatment selection, starting BMI and the exclusion of early discontinuers all limit that inference. Our guide to randomized trials and real-world evidence explains why treatment selection matters in a comparison like this.
Which medicine and whose costs?
Ozempic is the product the researchers studied. In the European Union it is authorized for adults with insufficiently controlled type 2 diabetes. Wegovy, which also contains semaglutide, has a separate weight-management indication for eligible patients. In Jbeil, the researchers observed a selected group of adults who continued the 1 mg weekly Ozempic regimen they describe. Our guide to Wegovy and Ozempic explains the product differences. EMA on Ozempic · EMA on Wegovy
The Lebanon study reported a lower average two-year treatment cost for Ozempic. A separate US study found higher two-year costs among insured patients receiving a mix of GLP-1 medicines than among patients who had surgery. That analysis counted pharmacy, medical and surgical spending in people with class II or III obesity. The studies differ in medicines, health systems and how they counted costs. A useful comparison for a patient needs costs for both options under the same coverage, with follow-up included. JPRAS Open, Table 2 · Barrett and colleagues in JAMA Surgery
What to ask about a two-year result
When reading a comparison like this, look for the starting measurements, the change over time and whether people who stopped or changed treatment were followed. For a discussion with a care team, it also helps to ask what follow-up each option requires and how costs might change over time. The Lebanese study gives a view of BMI among people who stayed with Ozempic and people who had surgery. It leaves comparative safety, outcomes after stopping the medicine and the results for everyone who starts treatment open. See our guide to reading weight-loss studies. Discussion and limitations


